Virological characteristics of the SARS-CoV-2 Omicron BA.2.75 variant

被引：102

作者：

Saito, Akatsuki ^{[1
,2
,3
]}

Tamura, Tomokazu ^{[4
]}

Zahradnik, Jiri ^{[5
,6
]}

Deguchi, Sayaka ^{[7
]}

Tabata, Koshiro ^{[8
]}

Anraku, Yuki ^{[9
,10
]}

Kimura, Izumi ^{[11
]}

Ito, Jumpei ^{[11
]}

Yamasoba, Daichi ^{[11
,12
]}

Nasser, Hesham ^{[13
,14
]}

Toyoda, Mako ^{[15
]}

Nagata, Kayoko ^{[16
]}

Uriu, Keiya ^{[11
,17
]}

Kosugi, Yusuke ^{[11
,17
]}

Fujita, Shigeru ^{[11
,17
]}

Shofa, Maya ^{[1
,2
]}

Begum, Mst Monira ^{[13
]}

Shimizu, Ryo ^{[13
]}

Oda, Yoshitaka ^{[18
]}

Suzuki, Rigel ^{[4
]}

Ito, Hayato ^{[4
]}

Nao, Naganori ^{[19
]}

Wang, Lei ^{[18
,20
]}

Tsuda, Masumi ^{[18
,20
]}

Yoshimatsu, Kumiko ^{[21
]}

Kuramochi, Jin ^{[22
,23
]}

Kita, Shunsuke ^{[9
,10
]}

Sasaki-Tabata, Kaori ^{[24
]}

Fukuhara, Hideo ^{[25
,26
]}

Maenaka, Katsumi ^{[9
,10
,25
,26
]}

Yamamoto, Yuki ^{[27
]}

Nagamoto, Tetsuharu ^{[27
]}

Asakura, Hiroyuki ^{[28
]}

Nagashima, Mami ^{[28
]}

Sadamasu, Kenji ^{[28
]}

Yoshimura, Kazuhisa ^{[28
]}

Ueno, Takamasa ^{[15
]}

Schreiber, Gideon ^{[5
]}

Takaori-Kondo, Akifumi ^{[16
]}

Shirakawa, Kotaro ^{[16
]}

Sawa, Hirofumi ^{[8
,19
,29
]}

Irie, Takashi ^{[30
]}

Hashiguchi, Takao ^{[31
]}

Takayama, Kazuo ^{[7
,32
]}

Matsuno, Keita ^{[29
,33
,34
]}

Tanaka, Shinya ^{[18
,20
]}

Ikeda, Terumasa ^{[13
]}

Fukuhara, Takasuke ^{[4
,35
]}

Sato, Kei ^{[11
,17
,36
,37
,38
,39
,40
]}

机构：

[1] Univ Miyazaki, Fac Agr, Dept Vet Sci, Miyazaki, Japan

[2] Univ Miyazaki, Grad Sch Med & Vet Med, Miyazaki, Japan

[3] Univ Miyazaki, Ctr Anim Dis Control, Miyazaki, Japan

[4] Hokkaido Univ, Fac Med, Dept Microbiol & Immunol, Sapporo, Hokkaido, Japan

[5] Weizmann Inst Sci, Dept Biomol Sci, Rehovot, Israel

[6] Charles Univ Prague, Med Fac 1, Biocev, Prague, Czech Republic

[7] Kyoto Univ, Ctr iPS Cell Res & Applicat CiRA, Kyoto, Japan

[8] Hokkaido Univ, Int Inst Zoonosis Control, Div Mol Pathobiol, Sapporo, Hokkaido, Japan

[9] Hokkaido Univ, Fac Pharmaceut Sci, Lab Biomol Sci, Sapporo, Hokkaido, Japan

[10] Hokkaido Univ, Fac Pharmaceut Sci, Ctr Res & Educ Drug Discovery, Sapporo, Hokkaido, Japan

[11] Univ Tokyo, Inst Med Sci, Dept Microbiol & Immunol, Div Syst Virol, Tokyo, Japan

[12] Kobe Univ, Fac Med, Kobe, Hyogo, Japan

[13] Kumamoto Univ, Joint Res Ctr Human Retrovirus Infect, Div Mol Virol & Genet, Kumamoto, Japan

[14] Suez Canal Univ, Fac Med, Dept Clin Pathol, Ismailia, Egypt

[15] Kumamoto Univ, Joint Res Ctr Human Retrovirus Infect, Div Infect & Immun, Kumamoto, Japan

[16] Kyoto Univ, Grad Sch Med, Dept Hematol & Oncol, Kyoto, Japan

[17] Univ Tokyo, Grad Sch Med, Tokyo, Japan

[18] Hokkaido Univ, Fac Med, Dept Canc Pathol, Sapporo, Hokkaido, Japan

[19] Hokkaido Univ, Int Inst Zoonosis Control, Div Int Res Promot, Sapporo, Hokkaido, Japan

[20] Hokkaido Univ, Inst Chem React Design & Discovery WPI ICReDD, Sapporo, Hokkaido, Japan

[21] Hokkaido Univ, Inst Genet Med, Sapporo, Hokkaido, Japan

[22] Interpk Kuramochi Clin, Utsunomiya, Tochigi, Japan

[23] Tokyo Med & Dent Univ, Dept Global Hlth Promot, Tokyo, Japan

[24] Kyushu Univ, Grad Sch Pharmaceut Sci, Dept Med Sci, Fukuoka, Japan

[25] Hokkaido Univ, Global Stn Biosurfaces & Drug Discovery, Sapporo, Hokkaido, Japan

[26] Hokkaido Univ, Int Inst Zoonosis Control, Div Pathogen Struct, Sapporo, Hokkaido, Japan

[27] HiLung Inc, Kyoto, Japan

[28] Tokyo Metropolitan Inst Publ Hlth, Tokyo, Japan

[29] Hokkaido Univ, One Hlth Res Ctr, Sapporo, Hokkaido, Japan

[30] Hiroshima Univ, Grad Sch Biomed & Hlth Sci, Hiroshima, Japan

[31] Kyoto Univ, Inst Life & Med Sci, Lab Med Virol, Kyoto, Japan

[32] Japan Agcy Med Res & Dev AMED, AMED CREST, Tokyo, Japan

[33] Hokkaido Univ, Int Inst Zoonosis Control, Int Collaborat Unit, Sapporo, Hokkaido, Japan

[34] Hokkaido Univ, Int Inst Zoonosis Control, Div Risk Anal & Management, Sapporo, Hokkaido, Japan

[35] Osaka Univ, Res Inst Microbial Dis, Lab Virus Control, Suita, Osaka, Japan

[36] Univ Tokyo, Int Res Ctr Infect Dis, Inst Med Sci, Tokyo, Japan

[37] Univ Tokyo, Int Vaccine Design Ctr, Inst Med Sci, Tokyo, Japan

[38] Univ Tokyo, Grad Sch Frontier Sci, Kashiwa, Chiba, Japan

[39] Kumamoto Univ, Joint Res Ctr Human Retrovirus Infect, Collaborat Unit Infect, Kumamoto, Japan

[40] Japan Sci & Technol Agcy, CREST, Kawaguchi, Saitama, Japan

来源：

CELL HOST & MICROBE | 2022年 / 30卷 / 09期

关键词：

VISUALIZATION; EXPRESSION; ALIGNMENT; CELLS; L452R; TOOL;

D O I：

10.1016/j.chom.2022.10.003

中图分类号：

Q93 [微生物学];

学科分类号：

071005 ; 100705 ;

摘要：

The SARS-CoV-2 Omicron BA.2.75 variant emerged in May 2022. BA.2.75 is a BA.2 descendant but is phylogenetically distinct from BA.5, the currently predominant BA.2 descendant. Here, we show that BA.2.75 has a greater effective reproduction number and different immunogenicity profile than BA.5. We determined the sensitivity of BA.2.75 to vaccinee and convalescent sera as well as a panel of clinically available antiviral drugs and antibodies. Antiviral drugs largely retained potency, but antibody sensitivity varied depending on several key BA.2.75-specific substitutions. The BA.2.75 spike exhibited a profoundly higher affinity for its human receptor, ACE2. Additionally, the fusogenicity, growth efficiency in human alveolar epithelial cells, and intrinsic pathogenicity in hamsters of BA.2.75 were greater than those of BA.2. Our multilevel investigations suggest that BA.2.75 acquired virological properties independent of BA.5, and the potential risk of BA.2.75 to global health is greater than that of BA.5.

引用

页码：1540 / +

页数：31

共 117 条

[1] PHENIX: a comprehensive Python']Python-based system for macromolecular structure solution [J].

Adams, Paul D. ;

Afonine, Pavel V. ;

Bunkoczi, Gabor ;

Chen, Vincent B. ;

Davis, Ian W. ;

Echols, Nathaniel ;

Headd, Jeffrey J. ;

Hung, Li-Wei ;

Kapral, Gary J. ;

Grosse-Kunstleve, Ralf W. ;

McCoy, Airlie J. ;

Moriarty, Nigel W. ;

Oeffner, Robert ;

Read, Randy J. ;

Richardson, David C. ;

Richardson, Jane S. ;

Terwilliger, Thomas C. ;

Zwart, Peter H. .

ACTA CRYSTALLOGRAPHICA SECTION D-STRUCTURAL BIOLOGY, 2010, 66 :213-221

[2]

[Anonymous], 2021, NAT MED, DOI DOI 10.1038/S41591-021-01283-Z

[3] Augmented neutralisation resistance of emerging omicron subvariants BA.2.12.1, BA.4, and BA.5 [J].

Arora, Prerna ;

Kempf, Amy ;

Nehlmeier, Inga ;

Schulz, Sebastian R. ;

Cossmann, Anne ;

Stankov, Metodi V. ;

Jaeck, Hans-Martin ;

Behrens, Georg M. N. ;

Pohlmann, Stefan ;

Hoffmann, Markus .

LANCET INFECTIOUS DISEASES, 2022, 22 (08) :1117-1118

[4]

Aryee Martin J., 2014, EUR J PUBLIC HEALTH, V30, P1363, DOI [10.1093/jac/dku393, DOI 10.1093/EURPUB/CKX232, 10.1093/bioinformatics/btu049]

[5] SARS-CoV-2 neutralizing antibody structures inform therapeutic strategies [J].

Barnes, Christopher O. ;

Jette, Claudia A. ;

Abernathy, Morgan E. ;

Dam, Kim-Marie A. ;

Esswein, Shannon R. ;

Gristick, Harry B. ;

Malyutin, Andrey G. ;

Sharaf, Naima G. ;

Huey-Tubman, Kathryn E. ;

Lee, Yu E. ;

Robbiani, Davide F. ;

Nussenzweig, Michel C. ;

West, Anthony P., Jr. ;

Bjorkman, Pamela J. .

NATURE, 2020, 588 (7839) :682-+

[6]

Barnes Christopher O., 2020, NATURE, V588, P682, DOI [10.1038/s41586-020-2852-1, DOI 10.1038/S41586-020-2010-9]

[7]

Beketova Elena, 2021, SCI REP-UK, V29, P264, DOI [10.1038/s41417-021-00327-3, DOI 10.1038/S41598-022-14655-3]

[8] Serum neutralization of SARS-CoV-2 Omicron sublineages BA.1 and BA.2 in patients receiving monoclonal antibodies [J].

Bruel, Timothee ;

Hadjadj, Jerome ;

Maes, Piet ;

Planas, Delphine ;

Seve, Aymeric ;

Staropoli, Isabelle ;

Guivel-Benhassine, Florence ;

Porrot, Francoise ;

Bolland, William-Henry ;

Nguyen, Yann ;

Casadevall, Marion ;

Charre, Caroline ;

Pere, Helene ;

Veyer, David ;

Prot, Matthieu ;

Baidaliuk, Artem ;

Cuypers, Lize ;

Planchais, Cyril ;

Mouquet, Hugo ;

Baele, Guy ;

Mouthon, Luc ;

Hocqueloux, Laurent ;

Simon-Loriere, Etienne ;

Andre, Emmanuel ;

Terrier, Benjamin ;

Prazuck, Thierry ;

Schwartz, Olivier .

NATURE MEDICINE, 2022, 28 (06) :1297-+

[9]

Bruel Timothee, 2022, NAT MED, V28, P1297, DOI [10.1038/s41591-022-01792-5, DOI 10.1038/S41591-022-01792-5]

[10]

Burke K., 1969, GRAMMAR MOTIVES, DOI [DOI 10.1525/9780520341715, 10.1525/9780520341715]

← 1 2 3 4 5 6 7 8 9 10 →